Drugmakers avert opioid trial as $48 billion settlement talk set to resume



by   |  VIEW 287

Drugmakers avert opioid trial as $48 billion settlement talk set to resume

On Tuesday, the 22nd of October 2019, four big-league US-based pharmaceutical companies accused of spurring an opioid epidemic of such scale which had been leading to an opioid overdose-related death every fifteen minutes in the United States, were expected to resume talks to reach a $48 billion settlement which in effect would make them immune to all opioid-related lawsuits in claims and liabilities.

In point of fact, Tuesday’s (October 22nd) landmark opioid trial for the pharmaceuticals comes forth over the heels of a $260 million deal with two of Ohio counties which in effect had averted their first ever federal trial over their mischievous marketing of opioid painkillers.

According to media reports, Israeli multinational drugmaker Teva Pharmaceuticals, alongside US-based drug distributor and pharmaceutical, AmerisourceBergen Corp., Cardinal Health Inc. alongside McKesson Corp. had immediately agreed to a deal with two of Ohio counties on Monday (October 21st) that in effect had rubbed out an imminent threat of a federal trial which was scheduled to begin in Cleveland.

Aside from that, an attorney for the towns and counties, Paul Hanly, had been quoted saying late on Monday (October 21st) that the parties could resume negotiations as early as Tuesday (October 22nd) to reach a broader agreement which would make them immune to thousands of opioid abuse related lawsuits filed by states, local governments and individual plaintiffs.